Michael Burry's Scion Asset Management has taken a long position in Zoetis (NYSE:ZTS), with the animal health giant trading down approximately 40% year-to-date and more than 70% below its 2021 peak, according to recent Substack disclosures from the famed investor.

Market Context

The broader healthcare sector has faced headwinds in 2026 as inflation pressures consumer spending across discretionary categories. Pet healthcare, often considered a defensive play, has not been immune—US pet owners have increasingly deferred routine veterinary visits and optional treatments amid elevated costs for food, housing, and general living expenses. This dynamic has created unusual pressure on companies like Zoetis that rely heavily on the US companion animal market.

Analysis

Burry's investment thesis centers on fundamental strength beneath the stock's dramatic decline. The investor points to Zoetis's gross margins exceeding 70%, which remain superior to peer benchmarks, alongside a balance sheet that carries less debt relative to competitors in the animal health space. At roughly 12 times forward earnings—compared to its historical average around 30 times—the valuation discount is substantial if the company can stabilize its core dermatology and parasite franchises.

The competitive landscape has deteriorated meaningfully. Elanco and Merck have gained ground in key categories, particularly skin treatments and parasiticides, areas where Zoetis historically dominated with approximately 86% of the US pet dermatology market. That dominance persists even as it erodes, suggesting the franchise retains value despite share loss. The FDA's recent emergency use authorization for Simparica Trio to treat New World screwworm in dogs provided a brief catalyst, demonstrating that novel approvals can still move shares when pipeline candidates reach commercialization.

On the fundamental side, fiscal Q2 2026 showed mixed results. Revenue was essentially flat year-over-year and down roughly 1% on an organic basis, with US revenue declining 7% offset by 6% international growth. Adjusted earnings per share still managed a 4% increase thanks to aggressive share buybacks. The dividend yield has expanded to nearly 3%—the highest in company history—with a payout ratio in the low 30s, providing income support for patient shareholders.

Return on equity running near 65% signals operational efficiency even amid revenue pressure. A pipeline including candidates targeting kidney disease, pain management, and obesity—and newly launched drugs Lenivia and Portela rolling out across Canada and Europe—provides optionality for future growth. Insider buying from directors during the stock's slide adds a minor constructive signal.

Key Numbers

- ZTS down approximately 40% year-to-date through mid-August 2026

- Stock has fallen more than 70% from its all-time high set in 2021

- Forward P/E of approximately 12x versus historical average near 30x

- Gross margins above 70%; return on equity approaching 65%

- Dividend yield at nearly 3%, with payout ratio in low 30s

- Approximately 86% US market share for pet dermatology drugs (down from peak)

- Q2 2026 revenue essentially flat; adjusted EPS up 4% on buybacks

What to Watch

The next quarterly earnings report will be critical in determining whether the Q2 stabilization represents a genuine inflection point or merely a pause in deterioration. Analysts maintaining mostly bullish ratings see roughly 70% upside to their average price target, though this assumes business conditions stabilize and pipeline drugs contribute meaningfully—outcomes that remain uncertain given competitive pressures and the years-long timeline for clinical candidates to reach peak penetration. The long-term debt load, which has grown in recent years, is manageable while profitability holds but would constrain financial flexibility if earnings declines accelerate.

Watch for any updates on the Simparica Trio emergency use expansion and whether Lenivia/Portela launches exceed initial expectations in Canada and Europe. Any commentary from management regarding competitive dynamics in parasiticides will also merit close attention.